Don’t let the high cost of Relistor disrupt your treatment. The Bausch Health Patient Assistance Program provides Relistor free of charge to eligible patients — with approvals in as little as 24–48 hours — and we manage your entire enrollment for a flat $69.95 per month.
The Relistor Patient Assistance Program is run by Bausch Health (which absorbed the former Salix patient assistance program) and provides both Relistor tablets and injections at no cost to qualifying patients: those with limited or no insurance coverage for the product, including Medicare Part D patients whose plans won’t cover it and — since late 2025 — a dedicated application track for Medicaid patients whose plans dropped coverage of Bausch/Salix medicines. Enrollment runs up to a year with dispenses of up to a 90-day supply, and approvals can come through in as little as 24 to 48 hours — unusually fast for this industry. Applying directly (1-833-862-8727, Mon–Fri 8 AM–8 PM ET) is always free. The harder parts are the ones around the form: documenting the insurance denial that unlocks eligibility, coordinating between your pain-management prescriber and the program, income paperwork, and annual renewals. For a flat $69.95 per month, our Patient Advocates handle every step — and for a condition this uncomfortable, the 24–48-hour fast track is worth doing right the first time.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens(brand) | ~$1,200/mo | Save substantially |
| CVS Pharmacy (brand) | ~$1,300/mo | Save substantially |
| Walmart(brand) | ~$800/mo | Save substantially |
| Costco(brand) | ~$720/mo | Save substantially |
| Generic naloxegol (Movantik) | ~$100/mo | Generic PAMORA alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Relistor — independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Relistor Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. OTC laxatives (PEG, senna, docusate) are very inexpensive first-line for most OIC patients; generic naloxegol is a substantially cheaper PAMORA alternative.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Relistor:
Coupon cards expire and require constant renewal
Still $700–$1,300 per month even with the best discount
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
Bausch Health reviews eligibility based on insurance status and household income. You will generally qualify if the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Relistor assistance:
Relistor (methylnaltrexone) is a peripherally acting mu-opioid receptor antagonist (PAMORA) — it blocks opioids’ effects in the gut without crossing into the brain, relieving opioid-induced constipation while leaving pain relief untouched.
How Relistor Works:
Opioids relieve pain through receptors in the central nervous system — but they hit the same receptors in the intestinal wall, slowing the gut to a crawl. That’s why opioid-induced constipation doesn’t respond well to ordinary laxatives: the cause is pharmacological, not dietary. Methylnaltrexone is built so it cannot meaningfully cross the blood-brain barrier — it displaces opioids from gut receptors only, restoring bowel function without triggering withdrawal or reducing analgesia.
Form and Use:
Relistor comes as 150 mg tablets (450 mg once daily on an empty stomach) for chronic non-cancer pain patients, and as a subcutaneous injection (8 mg or 12 mg strengths) — the injection is the form studied in advanced-illness patients receiving palliative care, where it can work within minutes to hours. The form choice drives cost structure: tablets are a standard monthly pharmacy fill, while injections price per syringe and can exceed tablets substantially at daily frequency. Program strategy should follow the prescribed form — something we confirm before filing.
Generic Availability:
There is no generic methylnaltrexone in the U.S., in either form — no generic applications have even been publicly reported, and patents run toward 2031. The related drugs Movantik (naloxegol) and Symproic (naldemedine) are same-class alternatives your prescriber might consider, but they are different molecules with their own pricing and coverage, not substitutes at the pharmacy counter. Until a generic arrives, the PAP and copay program are the levers.
Warnings:
Relistor should not be used with known or suspected bowel obstruction — and severe or persistent abdominal pain during treatment needs urgent evaluation, as rare gastrointestinal perforations have been reported in patients with conditions affecting the bowel wall. Stop and seek care for severe diarrhea. Opioid withdrawal symptoms (sweating, chills, anxiety, yawning) can occur, particularly in patients with disrupted blood-brain barriers. Tell your prescriber about kidney or liver impairment — doses adjust for both
Tablets run roughly $2,900–$3,400 per month (90 tablets at the standard 450 mg daily dose); daily injections can exceed $5,500 per month. Eligible patients can receive Relistor free through the Bausch Health Patient Assistance Program; our $69.95 monthly fee covers full advocacy and enrollment management.
Because the cause is the opioid itself binding receptors in your gut wall — a mechanism ordinary laxatives don’t touch. Relistor blocks those gut receptors directly, which is why it works when stool softeners and stimulants fail. If you’ve been cycling laxatives without relief while on opioids, that’s exactly the conversation to have with your prescriber.
Part D plans vary — some cover it with prior authorization, some don’t. Two protections apply: the $2,100 annual out-of-pocket cap (2026) if covered, and the Bausch PAP if your plan denies coverage — a denial letter actually unlocks the free-drug route, so a “no” from your plan is a document worth keeping, not a dead end.
No — the Copay Savings Program is commercial-insurance only. Medicare patients rely on the Part D cap, Extra Help if income-qualified, or the PAP after a coverage denial.
No — no generic methylnaltrexone exists in the U.S., with patents running toward 2031. Same-class alternatives (Movantik, Symproic) are different drugs requiring a prescriber decision, not substitutions.
Bausch’s program advertises approvals in as little as 24–48 hours with complete paperwork, and ships up to 90-day supplies — among the fastest programs we work with. “Complete paperwork” is the operative phrase: the missing denial letter or income document is what turns two days into six weeks, and preventing that is our job.
Relistor SC injection is approved for OIC in advanced illness (where rapid response matters). Relistor oral tablet, naloxegol, and naldemedine are approved for chronic non-cancer pain OIC. Different formulations and dosing schedules suit different patient situations.
Denials are usually about documentation — missing income proof, an insurance-status mismatch, or an inadequately documented coverage denial. Applications can be corrected and resubmitted. We review the denial letter, fix what triggered it, and resubmit on your behalf.
Relistor treats a condition patients are often too embarrassed to push back on — and too many quietly pay thousands or go without. Between a fast-approving free-drug program, a $0 copay card, and the Part D cap, nobody needs to. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.